A new chemical carcinogen and Western diet protocol to reliably induce advanced hepatocellular carcinoma in male and female mice

This study introduces a novel, reliable, and tolerable mouse model combining a lifelong Western diet with sequential low-dose diethylnitrosamine, thioacetamide, and sucrose water that successfully induces advanced-stage hepatocellular carcinoma in nearly 100% of both male and female mice while recapitulating human disease signatures.

The Gist

Imagine the liver as a busy, high-tech factory. Its job is to filter toxins, store energy, and keep the body running smoothly. Hepatocellular carcinoma (HCC) is like a rogue, out-of-control construction crew taking over that factory, building chaotic, useless structures (tumors) that eventually shut the whole place down.

For a long time, scientists trying to study this "factory takeover" in mice have faced a frustrating problem: their models were unreliable. It was like trying to predict a storm by looking at a single cloud. Sometimes the mice got sick, sometimes they didn't. Worse, the "sickness" often skipped female mice entirely, and when it did happen, the tumors were usually small and early-stage. This made it very hard to test new medicines, because you can't test a cure for a massive fire if your model only produces a tiny candle flame.

The "Perfect Storm" Recipe
The researchers in this paper decided to build a much more reliable "factory takeover" model. They created a specific recipe to ensure that 100% of male mice and 96% of female mice developed advanced, large tumors by the time they were about 7 months old (30 weeks).

Think of their recipe as a three-part "villain team" working together:

1. The Saboteur (DEN): They started with a chemical called Diethylnitrosamine (DEN). Imagine this as a tiny, invisible saboteur injected into the mice. It sneaks into the factory and starts tampering with the blueprints (DNA), creating errors that make cells grow uncontrollably.
2. The Stressor (Western Diet): Instead of feeding the mice healthy, plain food, they gave them a "Western Diet." This is like feeding the factory workers junk food and sugary drinks. It creates a stressful, chaotic environment that makes the cells more likely to turn rogue.
3. The Accelerator (TAA and Sugar Water): After the initial sabotage, they added Thioacetamide (TAA) in the water for a month. This is like pouring gasoline on a small fire. It damages the liver further and forces the cancer to grow faster. Finally, they switched the water to a sweet 10% sugar solution, which acts like a fertilizer, helping the tumors bloom.

The Result: A Perfect Match
The result was stunning. By the end of the experiment, almost every mouse had developed large, advanced tumors that looked and acted exactly like the aggressive liver cancer seen in humans.

But how did they know it was a good model? They didn't just look at the livers; they took a deep dive into the "factory's" inner workings:

• The Blueprint Check (Genetics): They used a high-tech scanner (spatial transcriptomics) to read the genetic instructions in the tumors. They found that the "rogue crew" was using the same bad instructions (genes) that human cancer cells use.
• The Employee ID Check (Proteins): They looked at the proteins (the workers) inside the tumors. They found specific markers, like FABP5 and PYGB, which are known to be high in human cancer patients but low in healthy people. These markers were also high in the mouse tumors.
• The Safety Check: They checked the blood for "leaks" (enzymes like ALT and AST) that indicate liver damage. The mice with tumors had high levels, just like human patients.

Why This Matters
Previously, testing a new drug for liver cancer was like trying to fix a broken car engine while driving on a bumpy road that might stop working at any moment. You couldn't be sure if the car stopped because of your fix or because the road was bad.

This new model is like a controlled, predictable test track. Because the scientists can now reliably create advanced cancer in both male and female mice, they can:

• Test new drugs with confidence.
• See if a treatment actually shrinks big, advanced tumors (not just tiny ones).
• Study why cancer behaves differently in men and women, since their model works for both.

In a Nutshell
The researchers found a way to reliably "break" the liver in mice so that it mimics the worst stages of human liver cancer. By combining a bad diet with a specific sequence of chemical attacks, they created a consistent, realistic model. This is a huge step forward because it gives scientists a solid foundation to finally find cures that actually work for the real-world, advanced liver cancer that kills so many people.

Technical Summary

1. Problem Statement

Hepatocellular carcinoma (HCC) is the most common liver malignancy and a leading cause of cancer death worldwide. Developing effective treatments requires preclinical mouse models that accurately mimic human disease progression. However, existing models face significant limitations:

• Sex Bias: Traditional models using the genotoxic carcinogen diethylnitrosamine (DEN) often result in low HCC incidence in female mice compared to males.
• Stage Variability: Even when HCC develops, the stage of progression is inconsistent, often failing to reach the advanced stages (Stage 2–3) where human patients are typically diagnosed and treated.
• Time and Reliability: Standard protocols can take 10+ months to induce tumors, and many mice fail to develop tumors entirely, hindering reliable therapeutic testing.

The authors sought to develop a tolerable, reliable, and rapid protocol that induces advanced-stage HCC in both male and female mice with a gene and protein profile comparable to human HCC.

2. Methodology

The study utilized C57BL/6 mice (both sexes) divided into a Low-Fat Diet (LFD) control group and a Western Diet (WD) group treated with chemical carcinogens (WD+DEN/TAA).

The Novel Protocol:

• Diet: Mice were placed on a high-fat, high-sucrose Western Diet (42% fat, 34% sucrose) immediately after weaning and maintained for life.
• DEN Administration: Starting at 2 weeks of age, mice received intraperitoneal injections of DEN once weekly for 8 weeks. The dosage was escalated: 20 mg/kg (Week 1), 30 mg/kg (Week 2), and 50 mg/kg (Weeks 3–8).
• TAA Administration: One week after the final DEN injection, mice were given drinking water containing 300 mg/L thioacetamide (TAA) for 4 weeks to induce liver damage and fibrosis.
• Sucrose Maintenance: Following a 2-week recovery with regular water, mice were switched to 10% sucrose water for the remainder of the study until euthanasia at 30 weeks of age.

Analytical Techniques:

• Histology & Imaging: H&E staining and Ki-67 immunohistochemistry (proliferation marker) were performed on liver sections.
• Spatial Transcriptomics: 10X Genomics Visium platform was used on FFPE tissue to map gene expression spatially across tumor and non-tumor regions.
• Proteomics & Western Blotting: Quantitative proteomics and Western blotting analyzed protein abundance (FABP5, PYGB, mTOR) in tumor vs. adjacent non-tumor tissue and compared them to human HCC samples.
• Metabolic Profiling: Promethion indirect calorimetry measured oxygen consumption, respiratory exchange ratio (RER), and whole-body glucose oxidation.
• Serum Biomarkers: ALT, AST, and Major Urinary Protein 20 (MUP20) levels were measured.

3. Key Contributions

• Sex-Neutral Efficacy: The protocol successfully induced advanced HCC in 100% of male mice and 96% of female mice by 30 weeks of age, resolving the historical sex bias in DEN models.
• Advanced Stage Induction: The model consistently produced Stage 2–3 HCC (defined by macroscopic tumor burden), with the majority of mice (26/27 males, 19/29 females) reaching Stage 3.
• High Tolerability: The protocol was well-tolerated, with a mortality rate of only 3.5% (2 out of 56 mice) prior to the 30-week endpoint.
• Translational Relevance: The model recapitulates human HCC molecular signatures, specifically validating the upregulation of FABP5, PYGB, and mTOR signaling, which are hallmarks of human advanced HCC.

4. Key Results

• Tumor Burden: All WD+DEN/TAA mice developed visible tumors (>2 mm). Males had a higher total tumor count than females, but tumor weight and size distributions were comparable between sexes.
• Histological Confirmation: H&E staining revealed clear cell carcinoma with large, irregular unstained areas and increased nuclear density. Ki-67 staining confirmed high proliferation rates in tumor tissues compared to controls.
• Molecular Profiling (Spatial Transcriptomics):
  • Identified four distinct clusters: two representing normal liver zones (periportal and perivenous) and two representing HCC clusters.
  • HCC clusters showed elevated expression of human HCC markers: FABP5, Lcn2, Afp (in large tumors), and Hdlbp (metastasis-associated).
• Protein Validation:
  • FABP5: Significantly elevated in mouse and human tumor tissue compared to non-tumor tissue.
  • PYGB: Upregulated in mouse tumors, mirroring human HCC.
  • mTOR: Increased phosphorylation (activation) of mTOR at Serine 2448 in tumors.
  • Proteomics: 153 proteins were up-regulated (enriched in ER/secreted pathways and terpenoid biosynthesis) and 161 were down-regulated (enriched in mitochondrial and steroid hormone pathways) in tumors vs. non-tumor tissue.
• Metabolic Changes: While oxygen consumption varied by sex and time of day, the protocol did not significantly alter whole-body glucose oxidation or physical activity, suggesting the metabolic shifts are localized to the liver/tumor microenvironment rather than systemic energy expenditure.

5. Significance

This study introduces a robust, reproducible, and sex-balanced preclinical model for advanced HCC. Its significance lies in:

1. Therapeutic Testing: It provides a reliable platform for screening new drugs for advanced HCC, a stage where current treatment options are limited and patient survival is low.
2. Mechanistic Insight: By matching human molecular signatures (FABP5, PYGB, mTOR), the model allows researchers to study the pathogenesis of HCC in a context that closely mimics human disease.
3. Efficiency: The 30-week timeline is significantly shorter than traditional DEN-only models, accelerating the drug development pipeline.
4. Inclusivity: By effectively modeling HCC in female mice, it addresses a critical gap in preclinical research, ensuring that potential therapies are tested across both sexes before human trials.

This protocol represents a major advancement in hepatocellular carcinoma research, offering a high-fidelity tool to bridge the gap between preclinical discovery and clinical application.